SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage
biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today
announced that it will report third quarter 2017 financial results after the U.S. financial markets close on Thursday, November 2,
2017. Folowing the announcement, MyoKardia senior management will host a conference call and live audio webcast at 4:30 p.m. ET to
discuss these results and provide a business update.
Conference Call and Webcast
To access the live conference call, please dial 844-494-0193 (domestic) or 508-637-5584 (international) and refer to the
conference ID 7295509.
The webcast may be accessed live on the Investor Relations section of the Company’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia
website for 90 days following the call.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is
on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from
biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a
pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic
cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly
MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical
studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial. MYK-491, MyoKardia’s second product
candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac
contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia
platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and
laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is
to change the world for patients with serious cardiovascular disease through bold and innovative science.
Contact:
Michelle Corral MyoKardia, Inc.
650-351-4690
mcorral@myokardia.com
